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Ophthalmologic complications with interferon therapy are rare and usually reversible. The anterior ischemic optic neuropathy
is an uncommon complication of interferon treatment. A case of irreversible anterior ischemic optic neuropathy complicating
interferon therapy for chronic hepatitis C is reported. We suggest that periodic ophthalmological examinations, including visual
acuity and fundus examinations, should be performed to patients with high risk of ocular complications after starting and during
treatment. We also suggest that an ophthalmologist would be able to detect these complications. Antiviral treatment should be
stopped immediately if severe ophthalmologic complications occur.
Ophthalmologic complications with interferon therapy are
rare,usuallymildandreversible,anddonotrequirethewith-
drawal of antiviral treatment [1]. Ophthalmologic complica-
tions with interferon alpha therapy, such as retinopathy with
cotton-wool spots, hemorrhages and macular edema, optic
neuropathy, and thrombotic microangiopathy occur in less
than1%oftreatedpatients.Individualswithdiabetes,hyper-
tension, dislipidemia, and hypercoagulable states are more
prone to develop those changes. In most cases, they are sub-
clinical, mild, and reversible, not requiring the withdrawal of
the treatment [2]. We report a case of a patient with chronic
hepatitis C who developed irreversible anterior ischemic
optic neuropathy during antiviral treatment by pegylated
interferon combined with ribavirin.
A 55-year-old man had chronic hepatitis C since 2008.
HCV genotype was 4, HCV-RNA level was 6,08·106 equiva-
lent/ml and the histological score of the liver biopsy was A2
F3 according to the METAVIR classiﬁcation. Pegylated inter-
feron (180 μg/week) combined with ribavirin (1000 mg/day)
was started in June 2008. HCV-RNA had been undetectable
since week 12 of the therapy. Five months after starting treat-
ment,thepatientpresentedwithasuddenbilateraldecreased
vision. Visual acuity was 2/10 in the left eye and 4/10 in
the right eye, while his visual acuity was previously normal.
Fundus examination revealed bilateral disc edema. Fluores-
cein angiography conﬁrmed the bilateral anterior ischemic
opticneuropathy.Therewasnoresponsetothevisualevoked
potentials in the either eye. The complete blood count chem-
istry,sedimentationrate,C-reactiveproteinlevel,antinuclear
antibodies, anti-DNA antibodies, and pANCA antibodies
were normal. Cryoglobulinemia was negative as were mag-
netic resonance imaging of the head, echocardiogram, and
carotidDopplerstudy.Antiviraltreatmentwasdiscontinued,
and the patient received methyl prednisolone 1g for 5 days.
An ophthalmologic examination one month later showed
that visual acuity had not clearly improved the visual acuity
was 3/10 for the left eye and 5/10 for the right one, while
optic disc oedema was partially resolved. HCV- RNA was
always undetectable six months and 1 year after interruption
of treatment, suggesting a sustained virological response.
Ophthalmologic examination after 1 years showed a visual
acuity of 3/10 for the left eye and 5/10 for the right one.
Anterior ischemic optic neuropathy is an uncommon
complication of interferon treatment which may dramati-
cally impair visual function. Few cases have been reported
in the literature [3] during antiviral treatment for chronic2 International Journal of Hepatology
hepatitis C [2] and also during interferon treatment of
cancer (2 cases), treatment of primary thrombocytemia (1
case),treatmentofmalignantmelanoma(1case),andduring
treatment of amyotrophic lateral sclerosis [4]. Predisposing
factors have not been clearly identiﬁed, except for classic
vascular risk factors (diabetes, arterial hypertension, and
dyslipidemia) [2]. In our patient’s case, no vascular risk
factors were found. Purvin and Col [5]h a ss u g g e s t e d
involvement of the posterior ciliary arterius rather than
the retinal vessels as a possible cause of anterior ischemic
optic neuropathy [5]. Lohmann and Coll hypothesized that
interferon could produce autoantibodies, and thus cause
desposition of immune complexes in the small retinal or
optic cytokines causing an inﬂammatory reaction of the
blood vessels that could then lead to ischemia [6]. The
favorable course is uncommon in anterior ischemic optic
neuropathy with vascular causes suggesting another mech-
anism [4]. The absence of resolution of anterior ischemic
optic neuropathy after discontinuation of interferon in our
patient suggests probable vascular causes. In the literature,
the course of anterior ischemic optic neuropathy occurring
during interferon treatment for chronic hepatitis C was
favorable in four cases [7], and not resolved in three cases [2,
4]. After interruption of the antiviral treatment, our patient
received methyl prednisolone, a steroid drug prescribed by
the ophthalmologists, without favorable course of visual
function.Intheliterature,twopatientsreceivedsteroidsafter
interferon treatment was discontinued, but there was no
improvement in visual function [3].
Anterior ischemic optic neuropathy is uncommon
unpredictable, and the frequency is unknown with inter-
feron therapy. Periodic ophthalmologic examinations before
starting treatment and during treatment particularly in
patientswithvascularriskfactorsmustbeindicated.Therapy
should be stopped immediately if severe ophthalmologic
complications occur.
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